Emergent BioSolutions to Resume Manufacturing Covid-19 Vaccine at Bayview Facility

Published on :

Emergent BioSolutions Inc. (NYSE:EBS) announced today that the U.S. Food and Drug Administration (FDA) is allowing Emergent’s Bayview manufacturing facility to resume production of Johnson & Johnson’s (J&J) Covid-19 vaccine bulk drug substance. This resumption of manufacturing follows extensive reviews by FDA, weeks of diligent work, and close coordination with J&J and FDA to execute on Emergent’s quality enhancement plan.

The Storied 25 Year History Behind the Baltimore Biotech Manufacturing Facility Producing COVID-19 Vaccines

Published on :

Emergent Biosolutions’ vaccine manufacturing plant in Baltimore has been the subject of many headlines this past year for its’ role in producing several COVID-19 Vaccines.  However, the history of this facility goes back more than two decades.

Rockefeller Foundation Grant Aims to Boost Vaccinations Among African American Communities

Published on :

Fueled by a $400,000 grant from The Rockefeller Foundation, the Black Women’s Health Imperative (BWHI), based in Washington, D.C., aims to improve vaccination rates among the African-American community through outreach programs and strategic partnerships with like-minded coalitions, including the National Caucus & Center on Black Aging (NCBA) and National Coalition of 100 Black Women (NCBW).

Maryland Governor Hogan Tours Site of Future Novavax Headquarters in Gaithersburg

Published on :

Governor Larry Hogan today toured the site of the future Novavax headquarters in Gaithersburg and celebrated the unveiling of plans for the new campus. Novavax is a clinical stage vaccine company that works to deliver novel products to prevent a broad range of infectious diseases, including COVID-19.

COVID-19 Vaccine Drug Substance Manufactured by Emergent BioSolutions Authorized as Part of Johnson & Johnson’s Emergency Use Authorization

Published on :

Emergent BioSolutions Inc. (NYSE:EBS) today announced that two batches of COVID-19 vaccine manufactured by Emergent BioSolutions at its Baltimore Bayview facility were determined to be suitable for use by the U.S. Food & Drug Administration (FDA) and have been authorized as part of Johnson & Johnson’s Emergency Use Authorization (EUA).

Norfolk’s ReAlta Life Sciences Receives $3.2 Million Grant from Virginia Catalyst to Accelerate Trial for the Treatment of Acute Lung Injury Due to COVID-19

Published on :

ReAlta Life Sciences (“ReAlta”), Inc., a company addressing life-threatening diseases through harnessing the power of the immune system, today announced that it has received a $3.2 million grant award from The Virginia Catalyst, also known as the Virginia Biosciences Health Research Corporation (VBHRC), to accelerate the Company’s Phase 1b clinical trial evaluating RLS-0071 for the treatment of acute lung injury (ALI) due to COVID-19. The award, which is granted to Virginia companies to support the acceleration of clinical testing of therapeutic drugs that treat life threating symptoms caused by COVID-19, includes additional funding for the Company’s research partner, Old Dominion University of Norfolk, Virginia, to explore other clinical biomarkers relevant for RLS-0071 treatment of COVID-19 patients.

UAB: Altimmune’s Intranasal COVID Vaccine Candidate Shows Sterilizing Immunity in Preclinical Tests

Published on :

University of Alabama at Birmingham researchers report additional preclinical evidence of the potency of a single-dose, intranasal COVID-19 vaccine candidate – AdCOVID – that was created by Altimmune Inc., a Maryland-based clinical-stage biopharmaceutical company.

Altimmune Demonstrates Strong Neutralization of South African Variant in Preclinical Study of Intranasal AdCOVID™

Published on :

Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced new results from a preclinical study demonstrating the ability of its AdCOVID vaccine candidate to neutralize the rapidly emerging SARS-CoV-2 B.1.351 variant of concern that originated in South Africa. B.1.351 carries multiple mutations in the receptor binding domain (RBD) including the E484K mutation that has been shown to substantially decrease the ability of authorized vaccines to neutralize the virus.